Sector News

Roche boosts digital health stable with MySugr buy

July 3, 2017
Life sciences

Roche has acquired MySugr, a privately held digital diabetes management player, for an undisclosed sum. MySugr’s apps will become a “focal part” of Roche’s strategy for integrated diabetes management.

Founded in 2012, in Vienna, MySugr focuses on app-based care for people with diabetes. Its offerings include the eponymous MySugr app, which automatically syncs data from a range of diabetes devices and provides feedback and motivation to help people manage their disease. It is available in 52 countries and 13 languages.

A user may purchase a “pro” version of the app with additional functions, such as bolus calculation and access to a certified diabetes educator, who gives personalized advice based on the individual’s diabetes data.

The company also offers some web apps and a pair of iOS apps, including a “scanner” app that allows users to transfer data from their blood glucose meter to the mySugr app by taking a picture of the meter’s screen.

“We are excited about this agreement, as we will be able to offer seamlessly accessible patient solutions within an open platform to better respond to the unmet needs of people with diabetes. Our aim is to support people with diabetes to spend more time in their ideal glucose target range and improve their quality of life,” said Roche Diabetes Care CEO Roland Diggelmann, in a statement.

MySugr counts Roche Venture Fund and iSeed Ventures among its investors.

The deal comes 4 months after reports emerged that the Swiss pharma was “considering options” for its diabetes care business, including a spinoff or a sale. At the time, Diggelmann put the rumors to rest, saying Roche was on the hunt for deals to prop up diabetes care, the sales of which sank 4% in fiscal 2016 thanks to pricing pressure in the U.S.

By Amirah Al Idrus

Source: Fierce Biotech

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).